Fellows and Residents
Pharmacotherapy Rounds
2009 - 2010 Schedule
Program Announcements
- By all Means Inhale: Cannabinoids in Palliative Care 025-000-09-017-L04-P
- Treatment of ICU Delirium 025-000-09-019-L04-P
- Hyperinsulnemic-Euglycemia for Calcium Channel Blocker Overdose 025-000-09-020-L04-P
- A Balanciing Act-The Pharmacist's Role in the Management of Patients with Comorbid Mild Traumatic Brain Injury, Post-Traumatic Stress Disorder and Pain 025-000-09-021-L04-P
- Can I Use an Atypical for that? Atypical use for Depression and Anxiety 025-000-09-022-L04-P
- In Two Shots: Ferumoxytol-A New Option for IV Iron 025-000-09-023-L04-P
- Update on the Safety of Drotecogin Alfa in the Treatment of Sepsis 0025-0000-09-029-L04-P
- Cognitive Behavioral Therapy and Exercise: A New Approach to Managing Fibromyalgia 0025-0000-09-032-L04-P
- No Water, No Pressure, No Vasopressin 0025-0000-09-033-L01-P
- Probiotics: Evaluating the Pros and Cons in the Role of Clostridium Difficile-Associated Diarrhea Prophylaxis 0025-0000-09-034-L01-P
- Pharmacologic Drug Therapy for Antibody Medicated Rejection 0025-0000-09-035-L01-P
- Getting Aggravated Over Platelet Aggregation: Assessing the Evidence of a Clopidogrel/PPH Interaction 0025-0000-09-036-L04-P
- Denosumab: A Novel Approach for Treating Osteoporosis 0025-0000-09-038-L01-P
- Vancomycin versus Linezolid for the Treatment of Nosocomial Pneumonia 0025-0000-09-040-L01-P
- DPP4-Inhibitors and their Place in the Management of Type 2 Diabetes Mellitus 0025-0000-09-041-L01-P
- Go With The Flow: Silodosin for Benign Prostatic Hypertrophy (BPH) 0025-0000-09-042-L04-P
- Pharmacotherapy of COPD: Improving Symptoms While Increasing Death? 0025-0000-09-043-L01-P
- Dronedarone: An Alternative Antiarrhythmic Agent for Atrial Fibrillation 0025-0000-09-044-L01-P
- Artesunate in the Treatment of Severe Malaria 0025-0000-10-001-L04-P
- Anticoagulation with Argatroban in Critically Ill 0025-0000-10-002-L04-P
- Flesh Eating Bacteria Claims Hand but Loses Battle to Survive: Necrotizing Fasciitis 0025-0000-10-003-L01-P
- Intensive Insulin Therapy in the ICU: Where Do We Stand in 2010? 0025-0000-10-004-L01-P
- In the Fog: Understanding "Chemo Brain" 0025-0000-10-005-L01-P
- Surviving the Storm: The Role of Beta Blockers in Traumatic Brain Injury 0025-0000-10-006-L04-P
- Defining the Role of Statins in Preventing Cerebral Vasospasms Associated with Subarachnoid Hemmorrhage 0025-0000-10-007-L01-P
- Liraglutide: A New GLP-1 Analogue for the Management of Type 2 Diabetes 0025-0000-10-008-L01-P
Additional Information
Who should attend?
Pharmacy residents, residency preceptors, faculty, and practicing pharmacists. This program is offered free of charge to participants and is supported only by the University of Maryland School of Pharmacy.
How is CE credit awarded?
Register on the sign-in sheet and complete evaluation form in order to receive your continuing education statement of credit by mail.
PLEASE NOTE: The evaluation form MUST BE SIGNED in order to receive CE credit.
How much credit is awarded?
1 CE Credit Contact Hour (0.1 CEUs).
Relevant Links
- Goals and Objectives 2009-2010
- Past Presentation Topics 2008-2009
- Past Presentation Topics 2007-2008
- Past Presentation Topics 2006-2007
Forms
- Pharmacotherapy Rounds Application 2009-2010
- Speaker Guidance
- Keywords for Pharmacotherapy Rounds Application
- Pharmacotherapy Rounds Checklist
- Pharmacotherapy Rounds Sign-In Sheet
- Pharmacotherapy Rounds Evaluation
Deadlines
- Topics for Pharmacotherapy Rounds must be submitted 90 days prior to presentation.
- Objectives, CV and Evaluation form must be submitted 45 business days prior to presentation.
- Presentation dates are randomly selected.
For more information, contact Melia Kendall at 410-706-8232 or Morgan Bukszar at 410-706-0761.
| The University of Maryland School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmaceutical education. These programs (UPN listed above) meet the ACPE criteria for 1.0 Contact Hour (0.1 CEU). Statements of credit will be mailed twice annually, within six months of the program (unless otherwise requested by the participant), to participants who successfully completed the program. Successful completion of the program requires your signature on the completed evaluation form and on the session sign in sheet and participation at the entire program for which you are seeking credit. Evaluation forms must be completed and returned at the conclusion of the program. This program is supported solely by the University of Maryland School of Pharmacy. |
| The Johns Hopkins Hospital Department of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |